Polypeptide combination for anchoring target protein on cell membrane and displaying target protein on outer side of cell membrane and application

By designing the fusion expression of polypeptides, the membrane anchoring and display of non-membrane proteins and secreted proteins is achieved, which solves the problem of false negative detection of cell indirect immunofluorescence method, expands the scope of application and improves the detection accuracy.

CN119019500APending Publication Date: 2024-11-26苏州锦芸生物医学科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410988114.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing cell-indirect immunofluorescence methods are prone to false negative problems when detecting non-membrane proteins and secreted protein target antigens, and the detection process is complicated, making it difficult to effectively display these proteins on the outer side of the cell membrane, limiting the sensitivity and specificity of the detection.

Method used

A polypeptide combination was designed to help non-membrane and secreted proteins anchor to the cell membrane and display the outer side of the cell membrane by fusing the signal peptide and membrane anchoring domain of type I membrane proteins, simplifying the detection process and reducing the risk of false negatives .

Benefits of technology

It effectively reduces the risk of false negatives in CBA method for detecting non-membrane proteins, expands the scope of application of the detection method, improves the sensitivity and specificity of the detection, and provides new tools for disease detection and development in the biopharmaceutical industry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019500A_ABST
    Figure CN119019500A_ABST
Patent Text Reader

Abstract

The invention discloses a polypeptide combination capable of anchoring a target protein on a cell membrane and displaying the target protein on the outer side of the cell membrane and application of the polypeptide combination. The polypeptide combination is (a) or (b): (a) a polypeptide combination composed of amino acid sequences as shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and (b) a derivative polypeptide combination which is obtained by substituting and / or deleting and / or adding one or more amino acid residues on the amino acid sequence as shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 and has the functions of anchoring the foreign protein on a cell membrane and displaying the foreign protein on the outer side of the cell membrane. The invention provides a target protein cell membrane targeted localization and display method, the risk that false negative is easy to occur when non-membrane protein is detected by a CBA method is effectively reduced, the application range of the detection method is expanded, and the method can be applied to the fields of disease detection and diagnosis, vaccines, pharmaceutical development and the like in the biological medicine industry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a polypeptide combination and application thereof for anchoring a target protein to a cell membrane and displaying it on the outside of the cell membrane. Background Art

[0002] Autoimmune diseases are diseases in which autoantibodies or sensitized T lymphocytes react with corresponding self-components, thereby causing tissue and organ damage and dysfunction. Usually, autoimmune diseases are often accompanied by the production of characteristic autoantibodies, such as antinuclear antibodies and anti-Sm antibodies in systemic lupus erythematosus, anti-nAChR antibodies in myasthenia gravis, anti-SSA and SSB antibodies in Sjögren's syndrome, etc. As an important serum marker for autoimmune diseases, rapid detection of autoantibodies has important application value for the diagnosis, treatment measures and prognosis of autoimmune diseases. At present, the main methods for detecting autoantibodies include: immunoblotting, enzyme-linked immunosorbent assay, indirect immunofluorescence, chemiluminescence, colloidal gold method, etc. With the continuous discovery of disease-related autoantibodies and the development of detection technology, the sensitivity and specificity of autoantibody detection have been correspondingly increased, and the diagnostic criteria for related autoimmune diseases have also been updated and adjusted accordingly. During the period of 2018 to 2020 [1-2], international and domestic neurology experts listed the cell-based indirect immunofluorescence (CBA) test as a consensus and recommendation for the diagnosis of autoimmune diseases such as neuromyelitis optica spectrum disorders and autoimmune encephalomyelitis.

[0003] The CBA method can be considered as a cell display system, which allows the target antigen to be detected to be expressed in cells and displayed on the cell surface. After incubation with the sample to be tested, the specific antibodies in the sample are qualitatively identified by a secondary antibody coupled to a fluorescent group. For autoantibodies that mainly use spatial conformation as the recognition feature, the correct folding of the target antigen is crucial. During the expression process, recombinant proteins often produce incorrect conformations due to modification changes, incorrect folding and other factors, affecting the accuracy of the test. Moreover, the separation and purification of recombinant proteins, especially membrane proteins, is quite time-consuming and labor-intensive. The biggest advantage of the CBA method is that it can provide the target protein with an expression and folding environment that is closest to the body, and maintain the natural conformation of the target antigen to the maximum extent. It can not only greatly reduce the problems of false positives and false negatives in the test, but also save the huge workload brought by protein purification.

[0004] With the deepening of research on autoimmune diseases, more and more target antigens related to pathogenesis have been discovered and reported. Different targets are located differently after being expressed in cells. For targets expressed on the membrane, such as AQP4, MOG, etc., the CBA method is simple and convenient, with good sensitivity and specificity. However, for non-membrane proteins such as GFAP and MAD5, they are mainly distributed intracellularly after expression. During detection, the cells need to be permeabilized to allow antibodies to enter, which not only increases the complexity of the detection, but also causes high background and increases the risk of false positives and false negatives. For target antigens that are secreted proteins such as LGI1 and IGLON5, it is difficult to obtain positive results even if the permeabilization step is added. Therefore, how to anchor these two types of target antigens to the cell membrane and display them on the outer surface of the cell membrane has become an urgent problem to be solved.

[0005] Signal peptides are the determining factors that guide the synthesis and transmembrane transfer of protein polypeptide chains. They are usually short peptide chains of 5-30 amino acids and are present at the N-terminus of most newly synthesized secretory proteins and membrane proteins. Based on the insertion mechanism of membrane proteins in the plasma membrane, they can be divided into four main types, among which the transport mechanism of type I membrane proteins is as follows: (i) First, a cleavable signal peptide sequence at the N-terminus of the protein mediates the synthesis of the protein in the endoplasmic reticulum, and then the stop-transfer sequence at the C-terminus prevents the transmembrane transfer of the polypeptide chain and anchors it to the membrane. (ii) The protein is transported from the endoplasmic reticulum to the Golgi apparatus through COPII-coated vesicles, and then transported to the cell plasma membrane through the secretory vesicles of the Golgi apparatus. The fusion of the vesicles and the plasma membrane locates the protein on the plasma membrane, and the part of the protein before the membrane anchoring region is displayed on the outside of the cell membrane. The above characteristics of the signal peptide and membrane protein transport mechanism lay the foundation for the design of an effective membrane localization and display system of the present invention. The combination of the signal peptide and the membrane anchoring domain used can locate the non-membrane protein in the cell membrane and display it on the outside of the cell membrane, thereby enhancing the effectiveness of protein cell membrane targeting. Summary of the invention

[0006] In view of the above problems, the purpose of the present invention is to provide a polypeptide combination and its application that can anchor the target protein to the cell membrane and display it on the outside of the cell membrane, provide a method for the cell membrane targeted positioning and display of proteins, effectively reduce the problem of false negatives in the CBA method for detecting non-membrane proteins, and expand the application scope of this detection method.

[0007] To achieve the above object, the technical solution adopted by the present invention is: a polypeptide combination that anchors the target protein to the cell membrane and displays it on the outside of the cell membrane, wherein the polypeptide combination is (a) or (b):

[0008] (a) a polypeptide combination consisting of the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2;

[0009] (b) A derivative polypeptide combination having the function of anchoring the expressed protein to the cell membrane and displaying it on the outside of the cell membrane, wherein one or more amino acid residues of the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 are substituted and / or deleted and / or added.

[0010] The signal peptide at the N-terminus of type I membrane protein is usually composed of 7-15 polar amino acid residues, and the stop transfer and membrane anchoring region at the C-terminus is usually an α-helical structure formed by 20-25 hydrophobic amino acids. According to its transport mechanism, the signal peptide and membrane anchoring structure of type I membrane protein are fused and expressed with a specific antigen in a certain order, which helps to anchor the non-membrane protein to the cell membrane and display it on the outside of the cell membrane, which is convenient for the detection of the target protein. The polypeptide S1 of the present invention contains 20 amino acids and performs the cytoplasmic membrane guidance function. The polypeptide M1 of the present invention contains 32 amino acids, the 1st to 22nd are the transmembrane regions of the Helical structure, and the 23rd to 32nd are the intracellular regions, which perform the membrane anchoring function. Both polypeptides S1 and M1 are selected from typical type I membrane proteins. In practical applications, for intracellular proteins, the N-terminus and C-terminus of the protein sequence need to be connected to polypeptide S1 and polypeptide M1 respectively to form a fusion protein; for secretory proteins, since their N-terminus has its own signal peptide, the C-terminus of the protein sequence can be directly connected to polypeptide M1 to form a fusion protein. The above schemes are helpful to drive the fusion expressed protein to be anchored on the cell membrane and displayed on the outside of the cell membrane, thereby increasing the effectiveness of exogenous protein expression in the cell.

[0011] The present invention also provides a gene encoding the polypeptide of claim 1, wherein the nucleotide sequence of the gene is (a), (b) or (c):

[0012] (a) the nucleotide sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4;

[0013] (b) a nucleotide sequence that hybridizes with the nucleotide sequence shown in SEQ ID NO: 3 and / or SEQ ID NO: 4 and encodes a polypeptide that has the function of anchoring the target protein to the cell membrane and displaying it on the outside of the cell membrane;

[0014] (c) a nucleotide sequence having 80% or more homology with the nucleotide sequence shown in SEQ ID NO: 3 and / or SEQ ID NO: 4 and encoding a nucleotide sequence having a transmembrane domain.

[0015] The present invention also provides a recombinant fusion protein containing the polypeptide or a combination thereof.

[0016] The recombinant fusion protein provided by the present invention contains the polypeptide or combination thereof that anchors the target protein to the cell membrane and displays it on the outside of the cell membrane. The specific target antigen gene is fused with the polypeptide of the present invention to express, so that the expressed antigen can be anchored to the cell membrane and displayed on the outside of the cell membrane. During detection, the antibody can bind to it without passing through the cell membrane, which can simplify the operation steps of the CBA detection method and reduce the risk of false negatives.

[0017] The invention also provides a recombinant expression vector, recombinant bacteria or transgenic cell line containing the gene.

[0018] The present invention also provides the use of the polypeptide combination in anchoring the target protein to the cell membrane and displaying it on the outside of the cell membrane.

[0019] The present invention also provides the use of the recombinant fusion protein in anchoring the target protein to the cell membrane and displaying it on the outside of the cell membrane.

[0020] The present invention also provides a method for anchoring a target protein to a cell membrane and displaying it on the outside of the cell membrane, wherein the polypeptide combination is used as a membrane targeting and anchoring membrane structure to anchor the target protein to the cell membrane and display it on the outside of the cell membrane.

[0021] As a preferred embodiment of the method of the present invention, it specifically comprises the following steps:

[0022] (1) Introducing the fusion gene into the target cell, thereby anchoring the target protein on the cell membrane of the target cell and displaying it on the outside of the cell membrane; the fusion gene includes, from upstream to downstream, a gene sequence encoding polypeptide S1, a gene sequence encoding the target protein, and a gene sequence encoding polypeptide M1;

[0023] (2) Introducing the fusion gene into the target cell, thereby anchoring the target protein on the cell membrane of the target cell and displaying it on the outside of the cell membrane; the fusion gene includes, from upstream to downstream, a gene sequence encoding the target protein and a gene sequence encoding the polypeptide M1.

[0024] The beneficial effects of the present invention are as follows: the present invention provides a polypeptide combination with cytoplasmic membrane targeting function and membrane anchoring function, and the polypeptide combination is used to sequentially fuse and express with a target protein, so that the target protein can be anchored to the cell membrane and displayed on the outside of the cell membrane after being expressed in the cell, providing a tool for efficiently displaying exogenous proteins on the cell surface for biotransformation; the method of the present invention for anchoring specific non-membrane targets such as GFAP and IGLON5 to the cell membrane effectively reduces the risk of false negatives in the detection of non-membrane proteins by the CBA method, expands the application scope of the detection method, and lays a foundation for the development of disease detection and diagnosis, vaccines and pharmaceutical research and development in the biomedicine industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is a fluorescence micrograph of the EGFP protein in the control group and the experimental group in Example 1.

[0026] Figure 2 Graph showing plasmid expression and GFAP localization in the control group and experimental group in Example 2.

[0027] Figure 3 Graph showing plasmid expression and IGLON5 localization in the control and experimental groups in Example 3. DETAILED DESCRIPTION

[0028] In order to make those skilled in the art better understand the technical scheme of the present invention, the present invention is described in detail below in conjunction with specific embodiments, but the present invention is not limited in any form. The test methods in the following embodiments are conventional methods unless otherwise specified. The test materials used are purchased from conventional biochemical reagent stores unless otherwise specified. In addition, any method and material similar or equal to the recorded content can be applied to the present invention, and the preferred implementation methods and materials described in the text are only for demonstration purposes.

[0029] Example 1 Localization of S1-EGFP-M1 fusion protein in 293T cells

[0030] 1. Construction of S1-EGFP-M1 fusion expression plasmid

[0031] 1. Design the gene sequence for fusion expression and synthesize the gene fragment: According to the structural characteristics of EGFP, the gene fragment S1-EGFP-M1 for fusion expression was designed, which consists of the S1 sequence followed by the full-length EGFP gene and then the M1 sequence. The fusion gene sequence was commissioned to be synthesized by a company. The nucleotide sequence of S1-EGFP-M1 is SEQ ID NO.5.

[0032] 2. Connect the synthesized S1-EGFP-M1 sequence to the vector: The pcDNA3.1 vector was provided by a gene synthesis company, and the synthesized S1-EGFP-M1 fusion fragment was connected to the vector multiple cloning site, named pcDNA3.1-S1-EGFP-M1 plasmid.

[0033] 3. Construction of control plasmid: The pcDNA3.1 vector was provided by a gene synthesis company, and the EGFP gene fragment was connected to the vector multiple cloning site, named pcDNA3.1-EGFP plasmid.

[0034] 2. Localization of fusion protein in 293T cells

[0035] 293T cells were transfected with the experimental group plasmid pcDNA3.1-S1-EGFP-M1 and the control group plasmid pcDNA3.1-EGFP to detect the expression and localization of EGFP in 293T cells. The specific method is as follows:

[0036] 1. Cell culture: The cultured 293T cells were digested into single cells with 0.25% trypsin and resuspended in DMEM medium containing 5% fetal bovine serum to a cell concentration of 4×10 5 cells / ml, and then inoculated into a 96-well cell culture plate, 100 μL / well, cultured at 37°C, 5% CO2 for 18-20 h, and transfected when the cell adhesion confluence was about 70%-80%.

[0037] 2. Prepare DNA / PEI mixture: dilute 2 μg of recombinant plasmid pcDNA3.1-S1-EGFP-M1 and pcDNA3.1-EGFP plasmid to 125 μL respectively with opti-MEM medium; then dilute 15 μL of 1 mg / mL PEI (polyetherimide) solution to 250 μL with opti-MEM medium, let stand at room temperature for 5 minutes, mix the two plasmid mixtures with 125 uL PEI solution respectively, and let stand at room temperature for 20 minutes.

[0038] 3. Transfection: Add 25 μL of the incubated DNA / PEI mixture to each well of a 96-well cell culture plate, mix gently, and continue culturing at 37°C and 5% CO2. Fix the cells after 18 hours.

[0039] 4. Result observation: The localization of pcDNA3.1-S1-EGFP-M1 in the experimental group and pcDNA3.1-EGFP in the control group was observed under a fluorescence microscope. The results are shown in Figure 1 . Figure 1 A The results showed that EGFP green fluorescent protein was expressed throughout the cell. Figure 1 B shows that the fusion protein S1-EGFP-M1 is mainly expressed on the cell membrane of 293T cells.

[0040] Example 2 Localization of the autoimmune brain target antigen GFAP expressed by fusion with polypeptides S1 and M1 in 293T cells

[0041] 1. Construction of S1-GFAP-M1 fusion expression plasmid

[0042] 1. Design the gene sequence for fusion expression and synthesize the gene fragment: According to the structural characteristics of GFAP, the gene fragment S1-GFAP-M1 for fusion expression was designed, which consists of the S1 sequence followed by the full-length GFAP gene and then the M1 sequence. The fusion gene sequence was commissioned to be synthesized by a company. The nucleotide sequence of S1-GFAP-M1 is SEQ ID NO.6.

[0043] 2. Connect the synthesized S1-GFAP-M1 sequence to the vector: The pIRES-EGFP vector was provided by a gene synthesis company, and the synthesized S1-GFAP-M1 fusion fragment was connected to the vector multiple cloning site, named pIRES-S1-GFAP-M1 plasmid.

[0044] 3. Construction of control plasmid: The pIRES-EGFP vector was provided by a gene synthesis company, and the GFAP gene fragment was connected to the vector multiple cloning site, named pIRES-GFAP plasmid.

[0045] 2. Expression and localization of fusion protein S1-GFAP-M1 in 293T cells

[0046] 293T cells were transfected with the experimental group plasmid pIRES-S1-GFAP-M1 and the control group plasmid pIRES-GFAP. The expression of the fusion protein was detected by observing the green fluorescence expression of the pIRES-EGFP vector, and the localization of the GFAP protein in 293 cells was detected by using a GFAP-specific antibody. The specific method is as follows:

[0047] 1. Cell culture: The cultured 293T cells were digested into single cells with 25% trypsin and resuspended in DMEM medium containing 5% fetal bovine serum to a cell concentration of 4×10 5 cells / ml, and then inoculated into a 96-well cell culture plate, 100 μL / well, cultured at 37°C, 5% CO2 for 18-20 h, and transfected when the cell adhesion confluence was about 70%-80%.

[0048] 2. Prepare DNA / PEI mixture: dilute 2 μg of recombinant plasmid pIRES-S1-GFAP-M1 and pIRES-GFAP plasmid to 125 μL with opti-MEM medium; then dilute 15 μL of 1 mg / mL PEI solution to 250 μL with opti-MEM medium, let stand at room temperature for 5 minutes, mix the two plasmid mixtures with 125 uL PEI solution, and let stand at room temperature for 20 minutes.

[0049] 3. Transfection: Add 25 μL of the incubated DNA / PEI mixture to each well of a 96-well cell culture plate, mix gently, and continue culturing at 37°C and 5% CO2. Fix the cells after 20 hours.

[0050] 4. Antibody incubation: The fixed cells were washed twice with PBS, 100 μL of 5% goat serum was added to each well for blocking for 30 min, washed 5 times with PBS, and samples containing GFAP-specific antibodies were added and incubated at room temperature for 30 min. After washing 5 times with PBS, red fluorescent-labeled goat anti-human IgG (H+L) secondary antibodies were added and incubated for 30 min. After washing 5 times with PBS, 100 μL of PBS was added to each well.

[0051] 5. Result observation: The expression of plasmid and GFAP localization in control group and experimental group were observed under fluorescence microscope. Figure 2 A) and experimental group (see Figure 2 D) Green fluorescence was observed in all of them, indicating that the recombinant plasmids were successfully expressed. After the control group was incubated with GFAP-specific antibodies, no red fluorescence was observed, indicating that although GFAP was expressed, it was not localized on the cell membrane (see Figure 2 B and Figure 2 C), while after incubation with GFAP-specific antibody, the experimental group showed obvious red fluorescence on the cell membrane, indicating that the S1-GFAP-M1 fusion protein was localized on the cell membrane (see Figure 2 E and Figure 2 F); Experiments show that through fusion expression, the combination of S1 and M1 polypeptides can effectively locate the target protein on the cell membrane.

[0052] Example 3 Localization of the autoimmune brain target antigen IGLON5 expressed by fusion with polypeptide M1 in 293T cells

[0053] 1. Construction of IGLON5-M1 fusion expression plasmid

[0054] 1. Design the gene sequence for fusion expression and synthesize the gene fragment: IGLON5 is a secretory protein, which carries a signal peptide sequence that is secreted into the extracellular space. Therefore, the gene fragment IGLON5-M1 for fusion expression is designed, which consists of the full-length gene of IGLON5 connected to the M1 sequence. The fusion gene sequence is commissioned to be synthesized by a company. The nucleotide sequence of IGLON5-M1 is SEQ ID NO.7.

[0055] 2. Connect the synthesized IGLON5-M1 sequence to the vector: The pIRES-EGFP vector was provided by a gene synthesis company, and the synthesized IGLON5-M1 fusion fragment was connected to the vector multi-cloning site, named pIRES-IGLON5-M1 plasmid.

[0056] 3. Construction of control plasmid: The pIRES-EGFP vector was provided by a gene synthesis company, and the IGLON5 gene fragment was connected to the vector multiple cloning site, named pIRES-IGLON5 plasmid.

[0057] 2. Expression and localization of fusion protein in 293T cells

[0058] 293T cells were transfected with the experimental group plasmid pIRES-IGLON5-M1 and the control group plasmid pIRES-IGLON5. The expression of the fusion protein was detected by observing the green fluorescence expression of the pIRES-EGFP vector, and the localization of the IGLON5 protein in 293T cells was detected by using an IGLON5-specific antibody. The specific method is as follows:

[0059] 1. Cell culture: The cultured 293T cells were digested into single cells with 0.25% trypsin and resuspended in DMEM medium containing 5% fetal bovine serum to a cell concentration of 4×10 5 cells / ml, and then inoculated into a 96-well cell culture plate, 100 μL / well, cultured at 37°C, 5% CO2 for 18-20 h, and transfected when the cell adhesion confluence was about 70%-80%.

[0060] 2. Prepare DNA / PEI mixture: dilute 2 μg of recombinant plasmid pIRES-IGLON5-M1 and pIRES-IGLON5 plasmid to 125 μL with opti-MEM medium; then dilute 15 μL of 1 mg / mL PEI solution to 250 μL with opti-MEM medium, let stand at room temperature for 5 minutes, then mix the two plasmid mixtures with 125 uL of PEI solution and let stand at room temperature for 20 minutes.

[0061] 3. Transfection: Add 25 μL of the incubated DNA / PEI mixture to each well of a 96-well cell culture plate, mix gently, and continue culturing at 37°C and 5% CO2. Fix the cells after 20 hours.

[0062] 4. Antibody incubation: The fixed cells were washed twice with PBS, 100 μL of 5% goat serum was added to each well for blocking for 30 min, washed 5 times with PBS, diluted IGLON5 specific antibody was added and incubated at room temperature for 30 min, washed 5 times with PBS, red fluorescent labeled goat anti-human IgG (H+L) secondary antibody was added and incubated for 30 min, washed 5 times with PBS, and 100 μL of PBS was added to each well.

[0063] 5. Observation of results: The expression of plasmids and the localization of IGLON5 in the control and experimental groups were observed under a fluorescence microscope. Figure 3 A) and experimental group (see Figure 3 D) Green fluorescence was observed in all samples, indicating that the recombinant plasmids were successfully expressed. After incubation with IGLON5-specific antibodies in the control group, no red fluorescence was observed, indicating that although IGLON5 was expressed, it was not localized on the cell membrane (see Figure 3 B and Figure 3 C), while after the experimental group was incubated with IGLON5-specific antibody, there was obvious red fluorescence on the cell membrane, indicating that the IGLON5-M1 fusion protein was localized on the cell membrane (see Figure 3 E and Figure 3 F); Experiments have shown that the M1 polypeptide can effectively localize secretory proteins on the cell membrane through fusion expression.

[0064] Finally, it should be noted that the above description is only a preferred embodiment of the present invention. Under the guidance of the present invention, those skilled in the art can make a variety of similar expressions without violating the purpose and claims of the present invention, and such changes fall within the scope of protection of the present invention.

Claims

1. A polypeptide and a combination thereof that anchors a target protein to a cell membrane and displays it on the outside of the cell membrane, characterized in that: The polypeptide and combination are (a) or (b); (a) a polypeptide combination consisting of the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; (b) A derivative polypeptide combination having the function of anchoring the target protein to the cell membrane and displaying it on the outside of the cell membrane, wherein one or more amino acid residues of the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 are replaced and / or deleted and / or added.

2. A gene encoding the polypeptide according to claim 1, characterized in that: The nucleotide sequence of the polypeptide is (a), (b) or (c); (a) the nucleotide sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4; (b) hybridizes with the nucleotide sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4 and encodes a nucleotide sequence that has the function of anchoring the target protein to the cell membrane and displaying it on the outside of the cell membrane; (c) a nucleotide sequence having 80% or more homology with the nucleotide sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4 and encoding a nucleotide sequence having a transmembrane domain.

3. A recombinant fusion protein comprising the polypeptide according to claim 1 or a combination thereof.

4. A recombinant expression vector, recombinant bacteria or transgenic cell line containing the gene according to claim 2.

5. The polypeptide combination according to claim 1 and its use in anchoring a target protein to a cell membrane and displaying it on the outside of the cell membrane.

6. Use of the recombinant fusion protein according to claim 3 in anchoring a target protein to a cell membrane and displaying it on the outside of the cell membrane.

7. A method for anchoring a target protein to a cell membrane and displaying it on the outside of the cell membrane, characterized in that: The polypeptide combination of claim 1 is used as an anchor membrane structure and the target protein is displayed on the outside of the cell membrane.

8. The method according to claim 7, characterized in that The specific steps include: (1) Introducing the fusion gene into the target cell, thereby anchoring the target protein on the cell membrane of the target cell and displaying it on the outside of the cell membrane; the fusion gene includes, from upstream to downstream, a gene sequence encoding polypeptide S1, a gene sequence encoding the target protein, and a gene sequence encoding polypeptide M1; (2) Introducing the fusion gene into the target cell, thereby anchoring the target protein on the cell membrane of the target cell and displaying it on the outside of the cell membrane; the fusion gene includes, from upstream to downstream, a gene sequence encoding the target protein and a gene sequence encoding the polypeptide M1.